Stockscreener 앱 받기
1.90
8.21%
-0.17
전일 마감가:
$2.07
열려 있는:
$2.07
하루 거래량:
788.89K
Relative Volume:
1.09
시가총액:
$50.51M
수익:
$50,000
순이익/손실:
$-41.60M
주가수익비율:
-1.1212
EPS:
-1.6946
순현금흐름:
$-20.20M
1주 성능:
-2.06%
1개월 성능:
+46.15%
6개월 성능:
+9.83%
1년 성능:
-15.18%
1일 변동 폭
$1.85
$2.07
1주일 범위
$1.81
$2.165
52주 변동 폭
$1.09
$3.244
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.90 | 55.03M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-01 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-21 | 개시 | Alliance Global Partners | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-22 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-01 | 개시 | Robert W. Baird | Outperform |
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
INmune Bio publishes preclinical study on brain injury link to Alzheimer’s - Investing.com
In mice, XPro1595 prevented amyloid rise after brain injury - Stock Titan
INmune Bio And 2 Other Promising Penny Stocks To Consider - simplywall.st
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Reports Positive Phase 2 XPro Data - t.co
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's disease at AAIC - marketscreener.com
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio reports imaging data from Alzheimer’s drug trial By Investing.com - Investing.com Nigeria
INmune Bio reports imaging data from Alzheimer’s drug trial - Investing.com
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC - The Manila Times
INmune Bio Reports Concordant MRI Biomarker Changes Supporting Early XPro Treatment Activity in Phase 2 Alzheimer’s Study - Quiver Quantitative
INmune Bio says XPro imaging data at AAIC show early Alzheimer’s brain changes - Stock Titan
Form 4 INmune Bio Inc For: 7 July By Investing.com - Investing.com South Africa
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan
Price to book forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Enterprise value to revenue forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Inmune Bio Inc outlines its immunotherapy focus as shares trade on Nasdaq - ad-hoc-news.de
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - 富途牛牛
Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth? - Sahm
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com South Africa
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - The Manila Times
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio (INMB) Proxy filing Summary - Quartr
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell Small Cap Completeness Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000 Growth Benchmark - marketscreener.com
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB) - TradingView
Inmune Bio total assets 2021-2025 - Statista
INmune Bio receives UK regulatory approval for RDEB treatment plan By Investing.com - Investing.com Australia
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inmune Bio Inc 주식 (INMB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
7,211 |
10,095 |
1,518,017 |
| Moss David J | Chief Executive Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
9,014 |
12,620 |
1,294,883 |
0.80%
2.11%
자본화:
|
볼륨(24시간):